mt1013
Peptideexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 28, 2021 (NCT04783090)
Timeline
Indications
Mechanism of action
- Parathyroid hormone receptorANTAGONIST
PTH1R antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284043 | Phase 1 | Nov 30, 2025 | Shaanxi Micot Technology Limited Company |
| NCT07122401 | Phase 3 | Sep 30, 2025 | Shaanxi Micot Technology Limited Company |
| NCT06690242 | Phase 2 | Nov 18, 2024 | Shaanxi Micot Technology Limited Company |
| NCT06976177 | Phase 2 | Jun 7, 2024 | Shaanxi Micot Technology Limited Company |
| NCT06747247 | Phase 2 | Apr 12, 2023 | Shaanxi Micot Technology Limited Company |
| NCT04783090 | Phase 1 | Jun 28, 2021 | Shaanxi Micot Technology Limited Company, WCCT Global |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shaanxi Micot Technology Limited Company | For profit | 6 | 6 | 3 | 2021 |
| WCCT Global | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1